Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...

MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...

Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...

However, Wall Street was unmoved, with Bernstein analyst Courtney Breen noting that HS-10535 will likely trail Lilly's (LLY) ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...

The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...

Merck threw its hat into the obesity race on Wednesday ... DPP-4 plays a role in glucose metabolism. The weight-loss pills space could be huge. But the field is getting crowded. It includes big names ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. Rising maternal ...